Menu Search
Equities

Venture Life Group PLC

17V:FRA

Venture Life Group PLC

Actions
  • Price (EUR)0.462
  • Today's Change0.00 / 0.00%
  • Shares traded100.00
  • 1 Year change-1.70%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024 08:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The principal activities of the Company are the development, manufacturing, and commercialization of healthcare products, including medical devices, food supplements and cosmetics for the ageing population. The Company's product portfolio includes products, such as the UltraDEX and Dentyl oral care product ranges; the Balance Activ range in the area of women's intimate healthcare; the Lift Glucose and Glucogel product ranges for hypoglycaemia; Gelclair, Xonrid, and Pomi-T for oncology support products provide symptomatic relief for some of the side effects associated with cancer and its treatment; the Procto-eze Plus product ranges for hemorrhoids, and other Dermatology products. The Company operates through two segments: Venture Life Brands and Customer Brands. The Company's subsidiaries include Venture Life Limited, Lubatti Limited, Periproducts Limited, HL Healthcare Ltd, and Venture Life Healthcare Ltd.

  • Revenue in GBP (TTM)51.41m
  • Net income in GBP921.00k
  • Incorporated2005
  • Employees165.00
  • Location
    Venture Life Group PLCUnit 12, The Courtyard, Eastern RoadBRACKNELL RG12 2XBUnited KingdomGBR
  • Phone+44 134 457 8004
  • Fax+44 134 474 2970
  • Websitehttps://www.venture-life.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.